Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission
Guardado en:
Autores principales: | Richard Carvajal, Shaheer Khan, Tejus Satish, Matt Levin, Angela J Yoon |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2806a1c1044342f6a2b86e88ba34f72b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Advances in the use of topical imiquimod to treat dermatologic disorders
por: Francesco Lacarrubba, et al.
Publicado: (2008) -
Is histological remission of ulcerative colitis achievable?
por: Oleg V. Knyazev, et al.
Publicado: (2021) -
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
por: Lars Ny, et al.
Publicado: (2021) -
Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
por: S. C. Sasson, et al.
Publicado: (2021) -
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
por: Sanju Cyriac, et al.
Publicado: (2021)